Pharmaceutical Technology

JULY 28, 2022

Roche’s Susvimo (ranibizumab sustained release formulation) follows a similar theme; patients who are implanted with Susvimo are expected to visit their doctor only twice a year to have the implant refilled so that the medicine can be delivered to their eyes continuously. The therapy received FDA approval in October last year.

Marketing 130

Marketing Gene Therapy FDA Approval Development 130

pharmaphorum

FEBRUARY 28, 2022

Many of the small challenges that face individual doctors and patients in seeking to find a solution for a rare disease also contribute to the difficulty of researching and developing an effective treatment. Once diagnosed, only 5% of rare diseases actually have an effective treatment. The outlook for rare disease R&D. Work to be done.

Gene Therapy 104

Gene Therapy Development Gene Medicine 104

pharmaphorum

SEPTEMBER 12, 2022

Across LabCorp , we innovate through science and technology, with access to approximately 2,500 [doctors] and PhDs and over 700 patients. The test informs HCPs through a comprehensive genomic and immune profiling test clinically and analytically validated for all solid tumours. Navigating barriers to access.

Genomics 105

Genomics Genome Clinical Trials Clinical Trials 105

Velocity Clinical Research

OCTOBER 4, 2023

Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it is opening greenfield clinical research sites in Bristol, Leicester, and Romford, demonstrating the company’s commitment to the U.K. The sites launch at a time when clinical trial activity in the U.K.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

Pharmaceutical Technology

FEBRUARY 28, 2023

This often puts patients in difficult situations where they are passed between doctors until a correct diagnosis is reached. There are 7,000 known rare diseases, most of which non-specialist healthcare professionals have never encountered before. Orphan drug development is expanding Change is happening.

Medicine 130

Medicine Marketing Production Drugs 130

pharmaphorum

MAY 10, 2022

And those doctors have been born with TikTok on the mind and they will not go with the communication from the previous millennium. Hutnik gave an example of her work with Spark Therapeutics to develop a product to teach haemophilia patients about gene therapy. The first Gen Z HCPs are reaching the practice.

Marketing 98

Marketing Gene Therapy Sales Branding 98

XTalks

MAY 17, 2024

Dr. Philipson’s transition to the biotech sector began with a position at UK-based biotech Trizell, where his efforts culminated in a gene therapy FDA submission for bladder cancer. The company also has a Phase II trial looking at setanaxib in patients with head and neck cancer. Can they do it?

Development 52

Development Drugs Clinical Trials Clinical Trials 52

WCG Clinical

JUNE 4, 2024

We started, you know, experimenting with different gene therapies and antisense therapies. Doctors actually like to write. One of the things it does, it would allow regulators to compare the trial results of a clinical trial to something. We developed our own mouse models and cell lines.

Research 52

Research Clinical Trials Clinical Trials Doctor 52

Pharma Marketing Network

FEBRUARY 27, 2025

Pharma brands can develop: Whitepapers on clinical trials showcasing drug effectiveness. For example, a LinkedIn article on the future of gene therapy can position a brand as an authority in genetic medicine, attracting biotech investors, researchers, and prescribing physicians.

Branding 52

Branding Marketing Compliance Pharma Companies 52

XTalks

JUNE 8, 2021

Novartis’ Zolgensma (onasemnogene abeparvovec) gene therapy has been making significant strides as of late, including dosing of the first Spinal Muscular Atrophy (SMA) patient with the treatment in the UK last week. Related: Is $2 Million Too Much For FDA-Approved SMA Gene Therapy? Zolgensma Gene Therapy: START Trial.

Gene Therapy 110

Gene Therapy Gene Protein Trials 110

FDA Law Blog

MARCH 13, 2023

Who better than people living with a condition to inform drug companies, physicians, academics, and the FDA on what it is like to live with their condition, what symptoms most impact their lives, what goes into their decision about whether to participate in a clinical trial, and what kind of treatment effects would be most meaningful to them?

Gene Therapy 98

Gene Therapy Gene Trials Clinical Trials 98

pharmaphorum

JANUARY 29, 2021

‘Cutting edge’ is, for once, a truly apt description when it comes to gene editing – both because the field is pushing medicine into areas we might never have dreamed possible, and because these technologies involve literally cutting DNA at a specific point in the genome. Gene therapy can ultimately only take you into the liver,” he explains.

Gene Editing 145

Gene Editing Gene Gene Therapy In-Vivo 145

Pharmaceutical Technology

AUGUST 12, 2022

Dr Merit Cudkowicz, a co-principal investigator in Amylyx’s clinical trials, says patients and investigators are pushing for an approval given the unmet need for therapies. “By Another objective deals with improving trial infrastructure and encouraging enrolment on decentralised clinical trials (DCT).

Research 246

Research Gene Therapy Drugs Trials 246

Advarra

MARCH 10, 2023

hindering progress on SCD – there is also a lack of clinical trials and research. Diversity in Clinical Trials and SCD As many clinical trials in the U.S. One reason for recruitment obstacles is generational fear of clinical trials due to their history.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Doctor 98

World of DTC Marketing

JANUARY 31, 2021

I have been recruited by these companies who promise huge payouts when they are acquired if their drug shows promise in clinical trials. Ex vivo (where cells are genetically modified outside the body) cell and gene therapies have generated considerable excitement on their potential to cure previously incurable diseases.

In-Vivo 187

In-Vivo Generic Drugs Drugs Gene Therapy 187

pharmaphorum

SEPTEMBER 21, 2021

Global Gene’s Craig Martin introduces a new patient identification initiative that strives to improve diagnosis and access to clinical trials for all patients with rare CNS conditions. Doctors are often unfamiliar with these conditions. Less than 5% of the more than 7,000 rare diseases have approved treatments.

Gene Therapy 90

Gene Therapy Gene Clinical Trials Clinical Trials 90

Pharmaceutical Technology

FEBRUARY 1, 2023

At the time of Synagis’s approval, it was believed that continuous improvements in monoclonal antibody therapy and RSV drug development would follow, says Dr. Janet Englund, professor of Paediatric Infectious diseases at the University of Washington. However, subsequent RSV drugs, like Medimmune’s motavizumab, failed in clinical trials.

Vaccine 162

Vaccine Vaccination Antibody Development 162

pharmaphorum

APRIL 16, 2021

Longer term challenges, such as the slowdown of HTA outputs, delays to clinical trials and regulatory submission, and the coming impact of economic crisis on medicines budgets will further challenge launch prognosis in the coming years. Once approved, launches do not necessarily become immediately commercially available. “For

Sales 95

Sales Marketing Medicine Doctor 95

pharmaphorum

APRIL 11, 2022

Janssen’s Catherine Taylor, vice-president, EMEA medical affairs, therapy area strategy, discusses the importance of systemic innovation across the healthcare system to realise the full value of medicines. Medicines and vaccines are among the most powerful interventions that can help improve quality of life for people across the world.

Medicine 115

Medicine Clinical Trials Clinical Trials Development 115

Pharma Marketing Network

JANUARY 20, 2021

Assuming these findings are replicated in clinical trials, this vaccine, with its more-appealing route of administration and convenient (refrigerator) storage requirements could make an important contribution to containing the disease.

Vaccine 52

Vaccine Vaccination In-Vivo Genetics 52

XTalks

DECEMBER 20, 2023

Originally launched in 2020 to encourage doctor visits during the pandemic, the BMS-Pfizer campaign, which also covers deep vein thrombosis and pulmonary embolism, aligned with the growing sales of their anticoagulant, Eliquis (apixaban). Read the full article for more insights into the dynamic field of life science consulting.

Life Science 59

Life Science Clinical Trials Clinical Trials FDA Approval 59